Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow 226002, U.P., India.
School of Pharmacy and Biomedical Sciences, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK.
J Control Release. 2022 Dec;352:931-945. doi: 10.1016/j.jconrel.2022.10.029. Epub 2022 Nov 15.
COVID-19 acquired symptoms have affected the worldwide population and increased the load of Intensive care unit (ICU) patient admissions. A large number of patients admitted to ICU end with a deadly fate of mortality. A high mortality rate of patients was reported with hospital-acquired septic shock that leads to multiple organ failures and ultimately ends with death. The patients who overcome this septic shock suffer from morbidity that also affects their caretakers. To overcome these situations, scientists are exploring progressive theragnostic techniques with advanced techniques based on biosensors, biomarkers, biozymes, vesicles, and others. These advanced techniques pave the novel way for early detection of sepsis-associated symptoms and timely treatment with appropriate antibiotics and immunomodulators and prevent the undue effect on other parts of the body. There are other techniques like externally modulated electric-based devices working on the principle of piezoelectric mechanism that not only sense the endotoxin levels but also target them with a loaded antibiotic to neutralize the onset of inflammatory response. Recently researchers have developed a lipopolysaccharide (LPS) neutralizing cartridge that not only senses the LPS but also appropriately neutralizes with dual mechanistic insights of antibiotic and anti-inflammatory effects. This review will highlight recent developments in the new nanotechnology-based approaches for the diagnosis and therapeutics of sepsis that is responsible for the high number of deaths of patients suffering from this critical disease.
COVID-19 相关症状已影响全球人口,并增加了重症监护病房(ICU)患者入院人数。大量 ICU 患者以死亡告终。据报道,医院获得性感染性休克导致大量患者死亡率较高,进而导致多器官衰竭,最终导致死亡。那些克服这种感染性休克的患者会遭受发病率的影响,这也会影响到他们的护理人员。为了克服这些情况,科学家们正在探索基于生物传感器、生物标志物、生物酶、囊泡等的先进技术的渐进式诊断治疗技术。这些先进技术为早期发现与败血症相关的症状并及时使用适当的抗生素和免疫调节剂进行治疗铺平了道路,防止对身体其他部位造成不必要的影响。还有其他技术,如基于压电机制原理工作的外部调制电基设备,不仅可以检测内毒素水平,还可以用加载的抗生素靶向它们,以中和炎症反应的发生。最近,研究人员开发了一种脂多糖(LPS)中和盒,它不仅可以检测 LPS,还可以通过抗生素和抗炎作用的双重机制见解进行适当的中和。这篇综述将重点介绍基于新纳米技术的败血症诊断和治疗方法的最新进展,这些方法是导致患有这种危急疾病的患者死亡人数众多的原因。